Dian He

Dr. Dian He


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KLKun Li
Kun Li
BWBaitao Wang
Baitao Wang
LZLifang Zheng
Lifang Zheng
KYKun Yang
Kun Yang
YLYuanyuan Li
Yuanyuan Li
DHDian He
Dian He

15 November 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HZHongtian Zhu
Hongtian Zhu
LTLei Tang
Lei Tang
CZChenghong Zhang
Chenghong Zhang
BWBaochu Wei
Baochu Wei
PYPingrong Yang
Pingrong Yang
YZYang Zhang
Yang Zhang
Chalcone derivatives, as a hot research field, exhibit a variety of physiological bioactivities and target multiple biological receptors. Based on the skeleton of (E)-1,3-diphenyl-2-propene-1-one, 14 chalcone derivatives were designed and synthesized, and evaluated as the antitumor candidates agents against four human cancer cell lines (A549, Hela, HepG2, and HL-60) as well as one normal cell line (WI-38). Among the title compounds, compound a14 showed better inhibitory activity against HepG2 cells (IC50 = 38.33 µM) and had relatively weak cytotoxicity towards normal cells WI-38 (IC50 = 121.29 µM). In this study, apoptosis, cycle arrest, assessment of reactive oxygen species (ROS) level, and measurement of mitochondrial membrane potential were adopted to explore the inhibitory mechanism of a14 towards HepG2. Compound a14 could effectively block the division of HepG2 cell lines in the G2/M phase and robustly induced generation of ROS, demonstrating that the generation of ROS induced by a14 was the main reason for resulting in the apoptosis of HepG2 cells. Moreover, the mitochondrial membrane potential (MMP) of HepG2 cells treated with a14 was significantly decreased, which was closely related to the enhanced ROS level. Furthermore, based on Western blot experiment, cell apoptosis induced by a14 also involved the expression of B-cell lymphoma-2 (Bcl-2) family and Caspase 3 protein. In summary, compound a14 could contribute to the apoptosis of HepG2 cells through regulating ROS-mitochondrial pathway, which provides valuable hints for the discovery of novel anti-tumor drug candidates.

10 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JTJing Tang
Jing Tang
DHDian He
Dian He
PYPingrong Yang
Pingrong Yang
JHJunquan He
Junquan He
YZYang Zhang
Yang Zhang
Glioblastomas (GBMs), are the most common intrinsic brain tumors in adults and are almost universally fatal. Despite the progresses made in surgery, chemotherapy, and radiation over the past decades, the prognosis of patients with GBM remained poor and the average survival time of patients suffering from GBM was still short. Discovering robust gene signatures toward better understanding of the complex molecular mechanisms leading to GBM is an important prerequisite to the identification of novel and more effective therapeutic strategies. Herein, a comprehensive study of genome-scale mRNA expression data by combining GBM and normal tissue samples from 48 studies was performed. The 147 robust gene signatures were identified to be significantly differential expression between GBM and normal samples, among which 100 (68%) genes were reported to be closely associated with GBM in previous publications. Moreover, function annotation analysis based on these 147 robust DEGs showed certain deregulated gene expression programs (e.g., cell cycle, immune response and p53 signaling pathway) were associated with GBM development, and PPI network analysis revealed three novel hub genes (RFC4, ZWINT and TYMS) play important role in GBM development. Furthermore, survival analysis based on the TCGA GBM data demonstrated 38 robust DEGs significantly affect the prognosis of GBM in OS (p < 0.05). These findings provided new insights into molecular mechanisms underlying GBM and suggested the 38 robust DEGs could be potential targets for the diagnosis and treatment.

15 April 2020 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
JHJunquan He
Junquan He
SWSongsong Wang
Songsong Wang
XLXingang Liu
Xingang Liu
RLRuili Lin
Ruili Lin
FDFang Deng
Fang Deng
YZYang Zhang
Yang Zhang
Vorinostat (SAHA) with great therapeutic potential has been approved by the FDA for the treatment of cutaneous T-cell lymphoma as the first HDACs inhibitor, but the drawbacks associated with hydroxamic acid group (poor stability, easy metabolism, weak binding ability to class IIa isozymes, and poor selectivity) have been exposed during the continuous clinical application. Based on the pharmacophore of HDAC inhibitors, two series of compounds with novel zinc binding group (ZBG) were designed and synthesized, and the antitumor bioactivities were evaluated in four human cancer cell lines (A549, Hela, HepG2, and MCF-7). Among the synthesized compounds, compounds a6, a9, a10, b8, and b9 exhibited promising inhibitory activities against the selected tumor cell lines, especially compounds a9 and b8 on Hela's cytostatic activity (a9: IC50 = 11.15 ± 3.24 μM; b8: IC50 = 13.68 ± 1.31 μM). The enzyme inhibition assay against Hela extracts and HDAC1&6 subtypes showed that compound a9 had a certain broad-spectrum inhibitory activity, while compound b8 had selective inhibitory activity against HDAC6, which was consistent with Western blot results. In addition, the inhibitory mechanism of compounds a9 and b8 in HDAC1&6 were both compared through computational approaches, and the binding interactions between the compounds and the enzymes target were analyzed from the perspective of energy profile and conformation. In summary, the compounds with novel ZBG exhibited certain antitumor activities, providing valuable hints for the discovery of novel HDAC inhibitors.

1 May 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KYKun Yang
Kun Yang
YLYuanyuan Li
Yuanyuan Li
QTQun Tang
Qun Tang
LZLifang Zheng
Lifang Zheng
DHDian He
Dian He

1 February 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
QZQiuping Zhang
Qiuping Zhang
YWYanni Wang
Yanni Wang
ZWZongyuan Wang
Zongyuan Wang
EMEyad Abdulwhab Hamoud Mohammed
Eyad Abdulwhab Hamoud Mohammed
QZQuan-Yi Zhao
Quan-Yi Zhao
ZWZhen Wang
Zhen Wang